2025 ECRC Webinar Series on Industry Collaborations!
This five-part webinar series highlighted the collaborative efforts between clinicians, scientists, and industry professionals in the clinical translation of innovative spinal cord injury (SCI) treatments and technologies. This series aimed to enhance and develop online educational resources that bridge the gap between industry, researchers, and clinicians, focusing on evidence-based practices and interdisciplinary collaboration.
|
ASIA ECRC 2025 Industry Collaborations Webinar Series Disclaimer The American Spinal Injury Association (“ASIA”) has made this webinar available to provide information to the spinal cord injury community in accordance with its mission. Reference in this webinar to any product or service does not constitute or imply an ASIA endorsement or recommendation of any company or such product or service. While ASIA has made every effort to include accurate information in the webinar, ASIA has not investigated or tested any of the products or services mentioned in the webinar, and it does not guarantee the accuracy, completeness, efficacy, or timeliness of such information, products, or services. ASIA is not responsible for, and expressly disclaims all liability for, any damage, injury or other loss of any kind arising out of use of or reliance on such information, products, or services, or any defect in or failure of any product or service or any misrepresentation or omission made in connection with such product or service. No guarantees or warranties, including (but not limited to) any express or implied warranties of merchantability or fitness for a particular use or purpose, are made by ASIA. |
Part 1: Robotic Exoskeletons | April 25th, 2025
Part 2: Spinal Cord Stimulation | May 30th, 2025
Part 3: Respiratory Rehabilitation Devices | August 1st, 2025
Focusing on Liberate Medical, this session will delve into the collaborative efforts to improve pulmonary care for SCI patients. Presenters will discuss their non-invasive VentFree Muscle Stimulator, designed to prevent muscle atrophy and reduce ventilator dependency in adults requiring mechanical ventilation.
Part 4: Gene and Cell Therapies | October 3rd, 2025
This session will explore the clinical translation of gene and cell therapies. Presenters from Inteligex, Aspen Neuroscience, and the Mayo Clinic Center for Regenerative Biotherapeutics will discuss the critical role of collaboration between clinical and scientific teams in developing therapies like autologous neuron replacement and regenerative stem cell treatments for SCI.
Part 5: Pharma | December 5th, 2025
In the final session, NervGen Pharma Corp. will present its work on nervous system repair, focusing on the collaboration between clinicians, scientists, and industry leaders in the development of therapies for SCI. Presenters will share their experiences in navigating the clinical translation process, including insights from ongoing trials.
Presenters:
Marc DePaul, PhD, Director of Research and NVG-291 Project Leader
Dr. Marc DePaul is the Director of Research at NervGen Pharma Corp. With over 15 years of experience in regenerative medicine, his work is dedicated to developing therapeutics that enhance nervous system repair by promoting plasticity, regeneration, and remyelination following injury or disease. His industry background is rooted in the preclinical development of cellular therapies for spinal cord injury, with experience as a Preclinical Scientist at Neurona Therapeutics and through a key scientific collaboration with Athersys Inc.
In his current role, Dr. DePaul directs the preclinical development for NervGen’s lead compound, NVG-291, for use in nerve repair applications. He earned his Ph.D. in Neuroscience and continued as a Postdoctoral Scholar at Case Western Reserve University, where his research was central to the development of the foundational technology upon which NervGen’s platform is built.
Adam Rogers, MD, Chair, Interim Chief Executive Officer
Dr. Adam Rogers was the Interim President of NervGen Pharma Corp. from September 2022 to April 2023 and is a Principal of Boston-based PFP Biosciences Holdings and is a board-certified ophthalmologist specializing in diseases and surgery of the retina and vitreous. Dr. Rogers co-founded Hemera Biosciences in 2010, a clinical stage gene therapy biotech company targeting dry age-related macular degeneration. He assumed the role of CEO in 2017 and oversaw all aspects of the company until the Hemera assets were acquired in December 2020 by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.
From 2001 to 2020 he served as an Assistant Professor of Ophthalmology at the New England Eye Center of Tufts Medical Center (Boston, MA). Dr. Rogers has published 29 articles in peer reviewed journals and co-authored two textbooks and numerous chapters in major ophthalmic textbooks. Since 2007 he has served on the board of One Family Inc., an organization whose mission is to end homelessness in Massachusetts. He is a member of the Emory University Board of Trustees. Dr. Rogers has a MD from Emory College and Emory School of Medicine.
